| Téléchargement | - Voir la version finale : Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens (PDF, 2.7 Mio)
|
|---|
| DOI | Trouver le DOI : https://doi.org/10.1016/j.heliyon.2022.e10270 |
|---|
| Auteur | Rechercher : Cholette, François; Rechercher : Fabia, Rissa; Rechercher : Harris, Angela; Rechercher : Ellis, Hannah; Rechercher : Cachero, KarlaIdentifiant ORCID : https://orcid.org/0000-0002-9039-3164; Rechercher : Schroeder, Lukas; Rechercher : Mesa, ChristineIdentifiant ORCID : https://orcid.org/0000-0001-8465-5474; Rechercher : Lacap, Philip; Rechercher : Arnold, CoreyIdentifiant ORCID : https://orcid.org/0000-0001-6552-6650; Rechercher : Galipeau, Yannick; Rechercher : Langlois, Marc-André; Rechercher : Colwill, KarenIdentifiant ORCID : https://orcid.org/0000-0002-8979-1659; Rechercher : Gingras, Anne-Claude; Rechercher : McGeer, Allison; Rechercher : Giles, Elizabeth; Rechercher : Day, Jacqueline; Rechercher : Osiowy, CarlaIdentifiant ORCID : https://orcid.org/0000-0002-5429-7220; Rechercher : Durocher, Yves1; Rechercher : Hankins, CatherineIdentifiant ORCID : https://orcid.org/0000-0002-1642-8592; Rechercher : Mazer, Bruce; Rechercher : Drebot, Michael; Rechercher : Kim, John |
|---|
| Affiliation | - Conseil national de recherches du Canada. Thérapeutique en santé humaine
|
|---|
| Bailleur de fonds | Rechercher : Canada Foundation for Innovation |
|---|
| Format | Texte, Article |
|---|
| Sujet | SARS-CoV-2; Covid-19; dried blood spots; serology; immunoassays; serosurveys |
|---|
| Résumé | The extent of the COVID-19 pandemic will be better understood through serosurveys and SARS-CoV-2 antibody testing. Dried blood spot (DBS) samples will play a central role in large scale serosurveillance by simplifying biological specimen collection and transportation, especially in Canada. Direct comparative performance data on multiplex SARS-CoV-2 assays resulting from identical DBS samples are currently lacking. In our study, we aimed to provide performance data for the BioPlex 2200 SARS-CoV-2 IgG (Bio-Rad), V-PLEX SARS-CoV-2 Panel 2 IgG (MSD), and Elecsys Anti-SARS-CoV-2 (Roche) commercial assays, as well as for two highly scalable in-house assays (University of Ottawa and Mount Sinai Hospital protocols) to assess their suitability for DBS-based SARS-CoV-2 DBS serosurveillance. These assays were evaluated against identical panels of DBS samples collected from convalescent COVID-19 patients (n = 97) and individuals undergoing routine sexually transmitted and bloodborne infection (STBBI) testing prior to the COVID-19 pandemic (n = 90). Our findings suggest that several assays are suitable for serosurveillance (sensitivity >97% and specificity >98%). In contrast to other reports, we did not observe an improvement in performance using multiple antigen consensus-based rules to establish overall seropositivity. This may be due to our DBS panel which consisted of samples collected from convalescent COVID-19 patients with significant anti-spike, -receptor binding domain (RBD), and -nucleocapsid antibody titers. This study demonstrates that biological specimens collected as DBS coupled with one of several readily available assays are useful for large-scale COVID-19 serosurveillance. |
|---|
| Date de publication | 2022-08-28 |
|---|
| Maison d’édition | Elsevier |
|---|
| Licence | |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Identificateur | S2405844022015584 |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | bc2882dc-9dff-4298-8e91-a7996502b335 |
|---|
| Enregistrement créé | 2023-10-26 |
|---|
| Enregistrement modifié | 2023-10-26 |
|---|
